Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC

Ann Oncol 2017; 28: 1339–1345 (doi: 10.1093/annonc/mdx075)

http://ift.tt/2nraoTg